Clinical trial NCT00322218: Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
Official title: Phase III,Open-label,Prospective,Two-armed,Multicenter Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Lymphoma, Large Cell, Diffuse
Lead sponsor: Spectrum Pharmaceuticals, Inc
Sponsor class: INDUSTRY
Collaborators: name: Bayer
First posted: 2006-05-05
Enrollment: 68
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study treats patients with diffuse large B-cell lymphoma whose disease is in complete remission due to previous treatment with Cyclophosphamide Doxorubicin hydrochloride Vincristine Prednisolone- Rituximab (CHOP-R). Half of the patients received Zevalin and the other half receive no further anti-cancer treatment. The two patient groups compared to determine if Zevalin given after CHOP-R therapy provides greater benefits than receiving no additional anti-cancer therapy after CHOP-R.

Detailed description: The objectives of this study were to evaluate the efficacy and safety of the Zevalin study regimen compared with observation alone in patients with complete remission (CR or CRu) after first-line CHOP-R, the study was to include patients 60-years-of-age or older with histologically confirmed Ann Arbor stage II, III, or IV diffuse large B-cell lymphoma

End Points:

Primary endpoint: Overall survival (OS) Secondary endpoints: Disease-free survival (DFS), health-related quality of life (HRQL) as assessed by the patient using standard questionnaires .

Number of Patients :

A total of 400 patients (200 per arm) were planned to be enrolled.

- In fact, 68 randomized patients (full analysis set; FAS) were analysed; 34 patients per each arm. The per-protocol set (PPS; 65 patients) comprised 33 patients allocated to the Zevalin arm and 32 patients allocated to the observation control arm.

Study Treatment :

The combination regimen with rituximab was designed in 2 steps as follows:

* Day 1: Initial administration of 250 mg/m\^2 rituximab, followed immediately by administration of 185 megabecquerel (MBq) (5 millicurie \[mCi\]) of \[111In\]-ibritumomab tiuxetan (the latter one only in centers where biodistribution imaging or dosimetry was compulsory according to local law). In centers where biodistribution imaging or dosimetry had not been required, the first rituximab infusion was given alone.
* Day 7-9: Rituximab 250 mg/m\^2, followed immediately by \[90Y\]-ibritumomab tiuxetan 14.8 megabecquerel/kilograms (MBq/kg) (0.4 millicurie / kilogram \[mCi/kg\]) (maximum dose 1184 MBq) given as a slow intravenous (I.V.) push over 10 minutes. Two treatment days one week apart followed by a 12-week safety period.

Duration of Patient Participation:

Due to the sequential design, the total duration of this study was not fixed. Originally, the study was planned in a randomized, parallel-group, group sequential design.

Objective :

The primary objective of this study was an inferential comparison between the 2 randomized groups in terms of overall survival using a group sequential triangular test ,since the study was prematurely terminated the pre-planned group-sequential nature of the study design was not applicable statistical analyses. Actually, the prominent efficacy variables for the OS and DFS were analysed in the FAS (identical to the safety analysis set) and PPS using Kaplan Meier estimates by treatment group.

Study Design :

This study was designed as a prospective, multi-center, open label, randomized, two-armed, group-sequential Phase III study. The study was planned to consist of 2 stages: an interventional Stage 1 with Screening/Baseline, treatment, safety, and follow-up periods, and a non-interventional Stage 2 consisting of a long-term follow-up period (until completion of a median observation period of 5 years). This second stage of the study was to be started only if superiority of the Zevalin study regimen could be demonstrated in the preceding Stage 1.

Pharmacokinetics/Pharmacodynamic results: Not applicable

Extent of exposure:

All 34 patients randomized to the Zevalin arm were given 2 rituximab infusions(with a median dose of 425.0 mg at each of the 2 infusion time points).Three patients underwent radioimaging studies/dosimetry and therefore were administered \[111In\]-ibritumomab tiuxetan at Day 1. All but 1 patient received an infusion with \[90Y\]-ibritumomab tiuxetan following the second infusion of rituximab. The mean dose ranged from 765.9 -1197.0 MBq.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed, Ann Arbor stage II, III, or IV Diffuse large B-cell lymphoma (DLBCL) according to the Revised European American Lymphoma(REAL)/World Health Organization (WHO) classification .
* Central pathology review confirming the DLBCL diagnosis and Cluster of differentiation 20 (CD20) positivity, and no evidence of DLBCL in bone marrow
* First-line treatment of DLBCL must have been 6 or 8 cycles of standard CHOP chemotherapy in combination with rituximab .
* Complete remission(CR) or unconfirmed complete remission(CRu) according to the International Workshop Response Criteria for Non Hodgkins Lymphoma (NHL) described by Cheson et al and modified for this study after first-line treatment with CHOP-R. Computerised Tomography (CT) scans of chest, abdomen, pelvis, and neck (if applicable) must have been performed within 6 weeks after the last dose of the last course of CHOP-R. Applicability of the neck CT means that the patient had involvement of the neck region by palpation / physical examination at first diagnosis (pre-CHOP-R).
* Central radiographic review of the CT scans from before and after first-line treatment with CHOP-R fulfilling the radiological requirements for CR/CRu
* Patients 60 years of age or older at time of randomization
* WHO performance status (PS) of 0 to 2 within 1 week of randomization
* Absolute neutrophil count greater than or equal to 1.5 x 10\^9/L within 1 week of randomization
* Hemoglobin greater than or equal to 10 g/dL within 1 week of randomization
* Platelets greater than or equal to 150 x 10\^9/L within 1 week of randomization
* Life expectancy of 3 months or longer
* Written informed consent obtained according to local guidelines

Exclusion Criteria:

* Presence of any other malignancy or history of prior malignancy except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma
* Prior radioimmunotherapy, radiation therapy, or any other NHL therapy except first-line CHOP-R
* Presence of gastric, central nervous system or testicular lymphoma at first diagnosis
* Histological transformation of low-grade non-Hodgkin's lymphoma (NHL)
* Known seropositivity for hepatitis C virus or hepatitis B surface antigen
* Known history of Human Immunodeficiency virus (HIV) infection
* Abnormal liver function: total bilirubin \> 1.5 x upper limit of normal (ULN) or Alanine Aminotransferase \> 2.5 x ULN within 1 week of randomization
* Abnormal renal function: serum creatinine \> 2.0 x ULN within 1 week of randomization
* Nonrecovery from the toxic effects of CHOP-R therapy
* Known hypersensitivity to murine or chimeric antibodies or proteins
* Granulocyte Colony Stimulating Factor (G-CSF) or Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) therapy within two weeks (or four weeks if pegylated) prior to screening laboratory sampling
* Concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes,congestive heart failure, myocardial infarction within 6 months of study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study
* Male and female patients of child-bearing potential unwilling to practice effective contraception during the study and unwilling or unable to continue contraception for 12 months after their last dose of study treatment
* Female patients who are pregnant or are currently breastfeeding
* Treatment with investigational drugs less than 4 weeks before the planned Day 1 or nonrecovery from the toxic effects of such therapy
* Surgery less than 4 weeks before the planned Day 1 or nonrecovery from the side effects of such surgery
* Concurrent systemic corticosteroid use for any reason except as premedication in case of known or suspected allergies to contrast media or as premedication for potential side effects of rituximab treatment
* Unwillingness or inability to comply with the protocol

Primary outcomes:
measure: Overall Survival (OS)
timeFrame: 5 years or until patient dies or lost to follow up
Secondary outcomes:
measure: Proportion of Participants With Disease Free Survival (DFS)
timeFrame: 5 years or until patient disease progresses or lost to follow up
measure: The Health-related Quality of Life (HRQL)
timeFrame: Up to Month 36
Other outcomes:
Locations:
city: Mesa
country: United States
facility: Research Site
state: Arizona
city: Phoenix
country: United States
facility: Research Site
state: Arizona
city: Scottsdale
country: United States
facility: Research Site
state: Arizona
city: Bakersfield
country: United States
facility: Research site
state: California
city: Berkeley
country: United States
facility: Research Site
state: California
city: Beverly Hills
country: United States
facility: Research Site
state: California
city: Burbank
country: United States
facility: Research Site
state: California
city: Duarte
country: United States
facility: Research Site
state: California
city: Los Angeles
country: United States
facility: Research site
state: California
city: Newport Beach
country: United States
facility: Research site
state: California
city: San Diego
country: United States
facility: Research Site
state: California
city: Vallejo
country: United States
facility: Research site
state: California
city: Aurora
country: United States
facility: Research site
state: Colorado
city: Newark
country: United States
facility: Research site
state: Delaware
city: Saint Petersburg
country: United States
facility: Research site
state: Florida
city: Coeur d'Alene
country: United States
facility: Research Site
state: Idaho
city: Chicago
country: United States
facility: Research site
state: Illinois
city: Joliet
country: United States
facility: Research site
state: Illinois
city: Morris
country: United States
facility: Research Site
state: Illinois
city: Overland Park
country: United States
facility: Research site
state: Kansas
city: Shreveport
country: United States
facility: Research Site
state: Louisiana
city: Baltimore
country: United States
facility: Research site
state: Maryland
city: Boston
country: United States
facility: Research site
state: Massachusetts
city: Detroit
country: United States
facility: Research site
state: Michigan
city: Rochester
country: United States
facility: Research Site
state: Minnesota
city: Saint Louis Park
country: United States
facility: Research Site
state: Minnesota
city: Commack
country: United States
facility: Research Site
state: New York
city: East Setauket
country: United States
facility: Research Site
state: New York
city: Durham
country: United States
facility: Research Site
state: North Carolina
city: Philadelphia
country: United States
facility: Research Site
state: Pennsylvania
city: Aberdeen
country: United States
facility: Research Site
state: South Dakota
city: Dallas
country: United States
facility: Research Site
state: Texas
city: Houston
country: United States
facility: Research Site
state: Texas
city: Norfolk
country: United States
facility: Research Site
state: Virginia
city: Graz
country: Austria
facility: Research Site
city: Innsbruck
country: Austria
facility: Research Site
city: Brugge
country: Belgium
facility: Research Site
city: Gent
country: Belgium
facility: Research Site
city: Leuven
country: Belgium
facility: Research Site
city: Edmonton
country: Canada
facility: Research Site
state: Alberta
city: Ottawa
country: Canada
facility: Research Site
state: Ontario
city: Toronto
country: Canada
facility: Research Site
state: Ontario
city: Montreal
country: Canada
facility: Research Site
state: Quebec
city: Helsinki
country: Finland
facility: Research Site
city: Oulu
country: Finland
facility: Research Site
city: Creteil
country: France
facility: Research Site
city: Dijon
country: France
facility: Research Site
city: Lille Cedex
country: France
facility: Research Site
city: Limoges
country: France
facility: Research Site
city: Lyon
country: France
facility: Research Site, Cedax
city: Paris Cedex
country: France
facility: Research Site
city: Toulouse Cedex
country: France
facility: Research Site
city: Chemnitz
country: Germany
facility: Research Site
city: Jena
country: Germany
facility: Research Site
city: Karlsruhe
country: Germany
facility: Research Site
city: Mainz
country: Germany
facility: Research Site
city: Rostock
country: Germany
facility: Research Site
city: Wurzburg
country: Germany
facility: Research Site
city: Budapest
country: Hungary
facility: Research Site
city: Debrecen
country: Hungary
facility: Research Site
city: Szeged
country: Hungary
facility: Research Site
city: Dublin
country: Ireland
facility: Research Site
city: Galway
country: Ireland
facility: Research Site
city: Bologna
country: Italy
facility: Research Site
city: Milan
country: Italy
facility: Research Site
city: Perugia
country: Italy
facility: Research Site
city: Pisa
country: Italy
facility: Research Site
city: Torino
country: Italy
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site, Yonsei
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Gdansk
country: Poland
facility: Research Site
city: Krakow
country: Poland
facility: Research Site
city: Poznan
country: Poland
facility: Research Site
city: Warsaw
country: Poland
facility: Research Site
city: Coimbra
country: Portugal
facility: Research Site
city: Lisbon
country: Portugal
facility: Research Site
city: Porto
country: Portugal
facility: Research Site
city: Singapore
country: Singapore
facility: Research Site
city: Madrid
country: Spain
facility: Research Site
city: Pamplona
country: Spain
facility: Research Site
city: Salamanca
country: Spain
facility: Research Site
city: Sevilla
country: Spain
facility: Research Site
city: Malmo
country: Sweden
facility: Research Site
city: Uddevalla
country: Sweden
facility: Research Site
city: Umea
country: Sweden
facility: Research Site
city: Bern
country: Switzerland
facility: Research Site
city: St Gallen
country: Switzerland
facility: Research Site
city: Bangkok
country: Thailand
facility: Research Site
city: Leicester
country: United Kingdom
facility: Research Site
city: London
country: United Kingdom
facility: Research Site
Study officials:
References: